Encorafenib, Cetuximab, and Binimetinib: Market Insights and Forecast for Cancer Treatments
Overview of Braftovi + Erbitux ± Mektovi Combination Therapy The combination of Braftovi (encorafenib), Erbitux (cetuximab), and optionally Mektovi (binimetinib) has become a pivotal treatment for certain cancer types, particularly metastatic colorectal cancer (mCRC) with the BRAFV600E mutation. This targeted therapy works by inhibiting both th